AstraZeneca launches health-tech business ‘Evinova’
Evinova will operate as a separate health-tech business within AstraZeneca
Evinova will operate as a separate health-tech business within AstraZeneca
The company has raised US$4.5 million in funding for its AI operating system
This product will be manufactured at Lupin’s Pithampur facility in India
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
The company expects that this development could improve the strength of its application to the FDA for new drug approval
Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Lupin enters into BTA with Lupin Manufacturing Solutions
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Subscribe To Our Newsletter & Stay Updated